SD BIOLINE HIV/Syphilis Duo

Same-day Test & Treatment
Current problems with Syphilis testing

- No ability to test and treat same day
- Requires electricity, instruments, laboratory equipment etc.
- HIV cannot be tested for at the same time
- Waiting for taking two tests in different site
- Blood collecting twice
- Patient has to revisit hospital for results
- Heavy workload
- Hard to access antenatal clinic (ANC) services: walking >1 hour

### Mean distance to the nearest health facility

<table>
<thead>
<tr>
<th>Country</th>
<th>Distance (km)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Niger</td>
<td>26.9</td>
</tr>
<tr>
<td>Zimbabwe</td>
<td>8.6</td>
</tr>
<tr>
<td>Madagascar</td>
<td>15.5</td>
</tr>
<tr>
<td>Haiti</td>
<td>8.0</td>
</tr>
<tr>
<td>Tanzania</td>
<td>4.7</td>
</tr>
<tr>
<td>Uganda</td>
<td>4.7</td>
</tr>
</tbody>
</table>

Adapted from: 1. World Health Organization (WHO)/TDR. The use of Rapid Syphilis Tests
Benefits of SD BIOLINE HIV/Syphilis Duo test

**Patients**
- Convenience of one sample
- Reduces time for testing
- Same day Test & Treatment
- Enables immediate partner notification

**Clinicians**
- Reduces workload
- Reduces training time
- Single procedure, two results

**Program Managers**
- No instruments, electricity or laboratory equipment required
- Increasing test coverage
- Cost-effective by reducing cost of storage, logistics, local distribution
- Contributes to MDG

---

**Acceptance Study**

**Background** (Maternity Hospital and Ventanilla-Callao, Peru)
- This study was carried out to evaluate the acceptability among ANC service providers.
- There were problems using separate HIV and Syphilis Rapid test from technicians
  - Confusion with reagent and results
  - Stock outs of HIV test
- SD BIOLINE HIV/Syphilis Duo tests were provided to 10 ANC health centers

**Results**
- 100% reported satisfaction with SD BIOLINE HIV/Syphilis Duo test
- 100% considered the SD BIOLINE HIV/Syphilis Duo test is better than separate test
- 32% mentioned difficulties with reading results (Now printed ‘HIV’ and ‘SYP’ below the test lines)

Adapted from: Acceptance of HIV/Syphilis Duo Rapid Testing: Survey of Attitudes of Antenatal Care Providers in Peru
Clinical Trials - Performance

The sensitivity and specificity of the SD BIOLINE HIV/Syphilis Duo test was consistently high across specimens from 6 countries around the world and it should be considered for improved HIV and syphilis screening coverage.

<table>
<thead>
<tr>
<th>Country</th>
<th>Detection of HIV Antibodies</th>
<th>Detection of Treponema pallidum Antibodies</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Sensitivity Estimate (exact 95% CI)</td>
<td>Specificity Estimate (exact 95% CI)</td>
</tr>
<tr>
<td>Ghana</td>
<td>100% (98.54%, 100%)</td>
<td>100% (97.57%, 100%)</td>
</tr>
<tr>
<td>Togo</td>
<td>100% (98.20%, 100%)</td>
<td>100% (96.61%, 100%)</td>
</tr>
<tr>
<td>Myanmar</td>
<td>100% (96.82%, 100%)</td>
<td>99.24% (95.82%, 99.98%)</td>
</tr>
<tr>
<td>Kenya</td>
<td>99.71% (98.40%, 99.99%)</td>
<td>100% (98.96%, 100%)</td>
</tr>
<tr>
<td>Mexico</td>
<td>100% (97.69%, 100%)</td>
<td>100% (99.01%, 100%)</td>
</tr>
<tr>
<td>Laos</td>
<td>100% (93.28%, 100%)</td>
<td>97.09% (91.72%, 99.40%)</td>
</tr>
<tr>
<td>Total</td>
<td>99.91% (99.51%, 100%)</td>
<td>99.67% (99.16%, 99.91%)</td>
</tr>
</tbody>
</table>

Clinical Trials - Cost Effectiveness

The dual point-of-care screening algorithm had lower overall costs and decreased life-time disability when compared to the other screening choices.

<table>
<thead>
<tr>
<th></th>
<th>Total Costs</th>
<th>Cost increase from no program</th>
<th>DALYs</th>
<th>DALYs prevented compared to no program</th>
<th>CER comparing screening to no program</th>
<th>ICER*</th>
</tr>
</thead>
<tbody>
<tr>
<td>No program</td>
<td>$20,783,454</td>
<td>-</td>
<td>269,400</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Dual HIV/syphilis</td>
<td>$21,274,678</td>
<td>$491,224</td>
<td>228,829</td>
<td>40,571</td>
<td>12.11</td>
<td>12.11</td>
</tr>
<tr>
<td>HIV test only</td>
<td>$21,583,611</td>
<td>$800,158</td>
<td>235,716</td>
<td>33,684</td>
<td>23.75</td>
<td>Strictly** dominated</td>
</tr>
<tr>
<td>Single rapid tests for HIV &amp; syphilis</td>
<td>$21,593,145</td>
<td>$809,692</td>
<td>235,023</td>
<td>34,377</td>
<td>23.55</td>
<td>Strictly** dominated</td>
</tr>
<tr>
<td>HIV rapid test &amp; RPR/TPPA for syphilis</td>
<td>$21,605,356</td>
<td>$821,902</td>
<td>235,094</td>
<td>34,306</td>
<td>23.96</td>
<td>Strictly** dominated</td>
</tr>
</tbody>
</table>

* Incremental cost effectiveness ratio (ICER) is the ratio of the change in costs to incremental benefit of an algorithm

** If an algorithm is both more costly and less effective than another algorithm it is considered “strictly dominated” and would not be recommended
Maximize PMTCT Service with

**HIV + SYPHILIS DUO**

Simple • Rapid • Accurate

Results in 20 minutes

Serum, Plasma, Whole blood

1-30°C

24 months

---

**Ordering Information**

<table>
<thead>
<tr>
<th>Cat. No.</th>
<th>06FK30</th>
<th>06FK35</th>
</tr>
</thead>
<tbody>
<tr>
<td>Specimen</td>
<td>S / P / WB</td>
<td>S / P / WB</td>
</tr>
<tr>
<td>Type</td>
<td>Device</td>
<td>Device</td>
</tr>
<tr>
<td>Pack size</td>
<td>25T/Kit</td>
<td>25T/Kit</td>
</tr>
<tr>
<td>Dimension</td>
<td>177x110x75 mm</td>
<td>177x110x75 mm</td>
</tr>
<tr>
<td>Weight</td>
<td>250g</td>
<td>300g</td>
</tr>
<tr>
<td>Contents</td>
<td>Devices, Diluent</td>
<td>Devices, Diluent, Capillary pipettes, Alcohol swabs, Lancets</td>
</tr>
<tr>
<td>Carton</td>
<td>565x415x395mm (55kits)</td>
<td>565x415x395mm (55kits)</td>
</tr>
<tr>
<td>Certification</td>
<td>CE Marked (06FK30CE, 06FK35CE)</td>
<td></td>
</tr>
</tbody>
</table>

---

**References**


---

© 2015 Alere. All rights reserved.
The Alere Logo, Alere and Knowing now matters are trademarks of the Alere group of companies. Any photos displayed are for illustrative purposes only. Any person depicted in such photos is a model.